JPMorgan raised the firm’s price target on BioMarin (BMRN) to $113 from $108 and keeps an Overweight rating on the shares. The firm adjusted the company’s model ahead of the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment
- BioMarin assumed with an Overweight at Morgan Stanley
- Positive Outlook for BioMarin Pharmaceutical Amid Competitive Challenges and Market Expansion Opportunities
- BioMarin Pharmaceutical’s Growth Potential and Competitive Edge Amidst Market Challenges
- BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN